Abstract Library

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,

#4121 The efficacy and safety analysis of transarterial embolisation in the treatment of cystic neuroendocrine neoplasm liver metastasis

Introduction: Liver metastases are common in neuroendocrine neoplasm (NEN). Cystic NEN liver metastases (cNENLM) are rare, and the efficacy of transarterial embolization (TAE) has not been reported.

Conference:

Presenting Author:

Authors: Yu H, Wang Y, Zhang N, Liu H, Chen L,

Keywords: Transaterial embolization, Neuroendocrine neoplasm, Liver metastasis, Cystic, Efficacy, Safety,

#4006 Efficacy, safety and prognostic factors of Capecitabine plus Temozolomide regimen in patients with thymic neuroendocrine neoplasms

Introduction: Thymic neuroendocrine neoplasms (T-NENs) are rare mediastinal malignancies that lack established treatment guidelines. While the Capecitabine and Temozolomide (CapTem) regimen has demonstrated significant efficacy in patients with pancreatic NENs, its applicability and effectiveness in treating T-NENs remain underexplored.

Conference:

Presenting Author: Liu M

Authors: Liu M, Yan X, Lin X, Chen L, Wang Y,

Keywords: Capecitabine plus Temozolomide, Thymic Neuroendocrine Neoplasm, CapTem, T-NEN,

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,